Megan Zhu

Investigations and Enforcement

Multiple multinational pharmaceutical, medical device and software companies in a series of internal investigations of their business operations in Asia Pacific (including mainland China, India and Japan) in connection with whistleblower allegations, bribery and corruption, books and records, improper patient interactions, revenue recognition and other compliance related issues.
Multiple independent investigations on behalf of the audit committees of the boards of directors of several U.S.-listed Chinese companies over whistleblower complaints and short-seller allegations relating to revenue recognition issues and financial frauds.
Several multinational companies in life science industry in investigations from Chinese governmental authorities related to suspected bribery misconduct, sponsorships and grants, and third party and distributor misconduct.

Compliance and Risk Assessment

A PRC communications module company in connection with trade controls and sanctions matters for its proposed H-share listing.
A PRC high-tech enterprise engaged in the R&D, design and manufacturing of PCBs in connection with trade controls and sanctions matters for its proposed H-share listing.
A PRC manufacturer specializing in the R&D and production of EV chargers in connection with trade controls and sanctions matters for its proposed H-share listing.

Cross-Border Litigation

A multinational data and software company on complex commercial litigation relating to claims concerning trade secret infringement, unfair competition, trademark and patent infringement.

Corporate

Multiple global pharmaceutical and medical device companies on general corporate and compliance matters in relation to their daily operations in China.
A leading pharmaceutical company in its acquisition of a Chinese state-owned pharmaceutical company.
A leading pharmaceutical company in its acquisition of clinics and advised on its business of an internet hospital in China.

Megan ZhuMeganZhu